InvestSMART

ResMed Inc. (ASX:RMD)

ALERT: Price-sensitive ASX Announcement for RMD
Current share price for RMD : $32.250 0.77 (2.45%)+
Announcement
Release
7 Aug 2026 8:26AM
Price at Release
$31.480
Full Release
download
Summary
ResMed Inc. announced strong financial results for the fourth quarter of fiscal year 2026, ending June 30, 2026. The company reported a 9% increase in Q4 revenue to $1.5 billion and a 2% increase in GAAP diluted earnings per share to $2.64, with non-GAAP earnings showing a 16% rise to $2.95. For the full fiscal year, revenue grew by 10% to $5.7 billion, and non-GAAP diluted earnings per share increased by 17% to $11.17. Operating cash flow stood at $1.8 billion, with free cash flow at $1.6 billion. The company highlighted its strategic focus on leveraging global scale and digital capabilities to enhance patient outcomes and reduce healthcare costs. ResMed plans to return over $1.85 billion to shareholders in FY 2027 through dividends and share repurchases, including a 10% increase in their quarterly dividend. Additionally, the company announced the sale of its MatrixCare business and the acquisition of Noctrix Health.
Key Points
  • ResMed's Q4 revenue increased by 9% to $1.5 billion.
  • GAAP diluted earnings per share rose 2% to $2.64.
  • Non-GAAP diluted earnings per share increased 16% to $2.95.
  • FY 2026 revenue grew by 10% to $5.7 billion.
  • Non-GAAP diluted earnings per share for FY 2026 increased by 17%.
  • Operating cash flow was $1.8 billion with free cash flow at $1.6 billion.
  • ResMed plans to return $1.85 billion to shareholders in FY 2027.
  • Quarterly dividend increased by 10% to $0.66 per share.
  • ResMed announced the sale of MatrixCare and acquisition of Noctrix Health.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.